Q1 25 EPS
$1.81
BEAT +2.11%
Est. $1.77
Q1 25 Revenue
$6.67B
MISS 2.14%
Est. $6.81B
vs S&P Since Q1 25
-9.2%
TRAILING MARKET
GILD +24.1% vs S&P +33.2%
Market Reaction
Did GILD Beat Earnings? Q1 2025 Results
Gilead Sciences delivered a steady Q1 2025, posting non-GAAP diluted EPS of $1.81 and total revenue of $6.67 billion as its core HIV franchise continued to shoulder the company's growth narrative. The HIV segment generated $4.59 billion in sales, up … Read more Gilead Sciences delivered a steady Q1 2025, posting non-GAAP diluted EPS of $1.81 and total revenue of $6.67 billion as its core HIV franchise continued to shoulder the company's growth narrative. The HIV segment generated $4.59 billion in sales, up 6% year-over-year, with Biktarvy climbing 7% to $3.15 billion and Descovy surging 38% to $586.00 million on stronger pricing and demand, though a 45% plunge in Veklury sales to $302.00 million kept headline revenue essentially flat. GAAP diluted EPS swung to $1.04 from a loss of $3.34 a year ago, a comparison heavily distorted by prior-year acquisition-related charges exceeding $6 billion. Gilead held its full-year product sales guidance at $28.20 billion to $28.60 billion and kept non-GAAP EPS guidance steady at $7.70 to $8.10, even as GAAP EPS guidance was trimmed slightly. Adding to the forward-looking picture, the company recently announced plans to expand its US investment to $32 billion by 2030, underscoring its long-term manufacturing and R&D ambitions alongside a closely watched June 19 PDUFA date for twice-yearly lenacapavir.
Key Takeaways
- • Biktarvy continued demand strength driving 7% sales growth
- • Descovy sales surged 38% on higher average realized price and demand
- • HIV portfolio benefited from higher average realized price and demand
- • Liver Disease demand growth in PBC, HBV, and HDV products
- • Disciplined expense management reduced R&D and SG&A spending
- • Absence of prior-year CymaBay acquisition charges and IPR&D impairments
GILD YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
GILD Revenue by Segment
With YoY comparisons, source: SEC Filings
GILD Revenue by Geography
With YoY comparisons, source: SEC Filings
“Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management. Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June PDUFA date for lenacapavir for HIV prevention, and continued progress across our diverse pipeline, we look forward to building on our positive momentum throughout the year.”
— Daniel O'Day, Q1 2025 Earnings Press Release
GILD Earnings Trends
GILD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GILD EPS Trend
Earnings per share: estimate vs actual
GILD Revenue Trend
Quarterly revenue: estimate vs actual
GILD Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.91 | $2.03 | +6.30% | $6.96B | +0.51% |
| Q4 25 BEAT FY | $1.83 | $1.86 | +1.88% | $7.93B | +3.21% |
| FY Full Year | $8.12 | $8.15 | +0.40% | $29.44B | +0.82% |
| Q3 25 BEAT | $2.14 | $2.47 | +15.67% | $7.77B | +4.14% |
| Q2 25 BEAT | $1.96 | $2.01 | +2.72% | $7.08B | +1.69% |
| Q1 25 BEAT | $1.77 | $1.81 | +2.11% | $6.67B | -2.14% |